Araştırma Makalesi

Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study

Cilt: 8 Sayı: 1 28 Şubat 2026
PDF İndir
TR EN

Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study

Öz

Objective: Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder frequently accompanied by autoimmune diseases. This study aimed to investigate the impact of coexisting autoimmune disorders, particularly celiac disease, on metabolic control and diabetic complications in patients with T1DM. Material and Methods: This retrospective cross-sectional study evaluated the prevalence of autoimmune diseases among patients with T1DM. Metabolic regulation and diabetic complications in patients with T1DM who also had celiac disease or Hashimoto’s hypothyroidism were compared with those in patients with T1DM alone. Results: Among 155 patients with T1DM, 26.5% had Hashimoto-related autoantibody positivity (n = 41), 7.7% had celiac-related autoantibody positivity (n = 12), and 1.9% had Graves-related autoantibody positivity (n = 3). Endoscopic duodenal biopsy was performed in three symptomatic patients with positive celiac autoantibodies, and histopathological findings consistent with celiac disease were identified in one patient. Eight seropositive patients declined biopsy but became asymptomatic after starting a gluten-free diet. No significant differences in metabolic control or diabetic complications were observed between patients with or without autoimmune comorbidities (p > 0.05). Conclusion: Although autoimmune disorders are more prevalent in individuals with T1DM than in the general population, they do not appear to influence glycemic regulation meaningfully. Nonetheless, routine screening remains advisable to enhance quality of life and reduce the burden of comorbidities.

Anahtar Kelimeler

Kaynakça

  1. Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 2019;15(11):635-650.
  2. Tuomela K, Levings MK. Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes. Diabetologia 2024;67(4):611-622.
  3. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol 2023;19(8):509-524.
  4. Ebrahimpour Y, Khatami S, Saffar M, et al. A comprehensive review of novel advances in type 1 diabetes mellitus. J Diabetes 2025;17(8):70120.
  5. Samuelsson J, Bertilsson R, Bülow E, et al. Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: a population-based study. Diabetologia 2024;67(4):679-689.
  6. Chalakova T, Yotov Y, Tzotchev K, et al. Type 1 diabetes mellitus - risk factor for cardiovascular disease morbidity and mortality. Curr Diabetes Rev 2021;17(1):37-54.
  7. Ogle GD, Wang F, Haynes A, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract 2025;225:112277.
  8. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine. J Pers Med 2023;13(3):422.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Endokrinoloji

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

28 Şubat 2026

Gönderilme Tarihi

15 Ekim 2025

Kabul Tarihi

10 Şubat 2026

Yayımlandığı Sayı

Yıl 2026 Cilt: 8 Sayı: 1

Kaynak Göster

APA
Menekşe, B., Cavnar Helvacı, B., Üçgül, E., & Çakal, E. (2026). Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study. Hitit Medical Journal, 8(1), 165-173. https://doi.org/10.52827/hititmedj.1803896
AMA
1.Menekşe B, Cavnar Helvacı B, Üçgül E, Çakal E. Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study. Hitit Medical Journal. 2026;8(1):165-173. doi:10.52827/hititmedj.1803896
Chicago
Menekşe, Burak, Burçak Cavnar Helvacı, Enes Üçgül, ve Erman Çakal. 2026. “Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study”. Hitit Medical Journal 8 (1): 165-73. https://doi.org/10.52827/hititmedj.1803896.
EndNote
Menekşe B, Cavnar Helvacı B, Üçgül E, Çakal E (01 Şubat 2026) Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study. Hitit Medical Journal 8 1 165–173.
IEEE
[1]B. Menekşe, B. Cavnar Helvacı, E. Üçgül, ve E. Çakal, “Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study”, Hitit Medical Journal, c. 8, sy 1, ss. 165–173, Şub. 2026, doi: 10.52827/hititmedj.1803896.
ISNAD
Menekşe, Burak - Cavnar Helvacı, Burçak - Üçgül, Enes - Çakal, Erman. “Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study”. Hitit Medical Journal 8/1 (01 Şubat 2026): 165-173. https://doi.org/10.52827/hititmedj.1803896.
JAMA
1.Menekşe B, Cavnar Helvacı B, Üçgül E, Çakal E. Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study. Hitit Medical Journal. 2026;8:165–173.
MLA
Menekşe, Burak, vd. “Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study”. Hitit Medical Journal, c. 8, sy 1, Şubat 2026, ss. 165-73, doi:10.52827/hititmedj.1803896.
Vancouver
1.Burak Menekşe, Burçak Cavnar Helvacı, Enes Üçgül, Erman Çakal. Autoimmune Comorbidities and Metabolic Outcomes in Type 1 Diabetes: A Retrospective Cross-Sectional Study. Hitit Medical Journal. 01 Şubat 2026;8(1):165-73. doi:10.52827/hititmedj.1803896